Aptevo (APVO) - יחס רווח גולמי

Aptevo Therapeutics (APVO) develops antibodies to combat oncology and autoimmune disorders using the ADAPTIR system. The business is currently transitioning into a growth phase, focusing on targeted blood therapies. Historical gross margin helps mitigate volatility, and its value has stabilized at 0.00. The company's prospects depend on the success of the drug mipitamonig and the expansion of medical partnerships.
פילוחי מדדים מקיפים ואנליטיקה עבור Aptevo (APVO)

Gross margin determines direct production efficiency by measuring the share of profit from sales after deducting variable costs. Analyzing the net gross margin allows for an assessment of a business's ability to generate excess cash flow to cover operating expenses. For Aptevo Therapeutics (APVO), this metric reflects the profitability of the ADAPT platform and the monetization of its patent portfolio through long-term licensing agreements with pharma behemoths.